• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

J&J’s Janssen touts Ph3 data for antidepressant nasal spray

May 7, 2018 By Sarah Faulkner

JanssenJohnson & Johnson‘s (NYSE:JNJ) Janssen revealed data today from two Phase III trials of its investigational esketamine nasal spray in patients with treatment-resistant depression.

The Titusville, N.J.-based company said that if approved by the FDA, esketamine would represent one of the first new approaches designed to treat refractory major depressive disorder in the last 50 years.

In a study of adults with treatment-resistant depression, Janssen found that flexibly-dosed esketamine nasal spray plus a newly-initiated oral antidepressant resulted in a statistically significant reduction of symptoms compared to a placebo spray combined with a newly-initiated oral antidepressant.

In a second study, patients ages 65 and older with treatment-resistant depression experienced a clinically meaningful reduction of symptoms with the nasal spray-oral drug combination compared to patients taking a placebo-oral drug combination. But Janssen noted that the difference was not statistically significant and the trial missed its primary endpoint.

“With about 30% of patients with major depression failing to respond to currently available antidepressants, treatment-resistant depression represents a major public health need,” Dr. Husseini Manji, global head of the neuroscience therapeutic area in Janssen’s R&D unit, said in prepared remarks.

“The positive Phase III results for esketamine nasal spray in adults with treatment-resistant depression are exciting, particularly as they mark the first time an antidepressant has achieved superiority versus an active comparator in any clinical trial for major depressive disorder. What makes this even more significant is that the response was rapid and this milestone was achieved in patients deemed to be treatment-resistant. We are also pleased with the clinically meaningful outcomes for esketamine nasal spray in elderly patients, a population that often has greater disability and lower response rates,” Manji added.

“There’s a critical need for new, rapidly acting and effective treatment options for people with major depressive disorder who do not respond to existing therapies,” Dr. Mathai Mammen, global head of R&D at Janssen, said. “Janssen is fully committed to exploring the newest science in the area of mood disorders and bringing these discoveries to patients in need.”

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Neurological, Pharmaceuticals, Wall Street Beat Tagged With: janssen, johnsonandjohnson

IN CASE YOU MISSED IT

  • BD stock up on Street-beating preliminary quarterly revenue numbers
  • Locate Bio lands FDA breakthrough nod for bone infection device
  • PerkinElmer to acquire Oxford Immunotec
  • Evonik buys polymers business from Durect Corp.
  • New Croatian notified body designated to European MDR

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by DrugDeliveryNow

Footer

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS